Drug Modeling Software Market Size, Share & Growth [2031]
Drug Modeling Software Market Size, Share & Growth [2031]
Segments - Drug Modeling Software Market by Component (Services and Software), Deployment Mode (Hybrid, Cloud, and On-premise), Enterprise Size (Small & Medium Enterprises and Large Enterprises), Application (Medical Imaging, Protein Modeling, Cheminformatics, Drug Discovery & Development, Graphical Molecular Modeling, High Throughput Virtual Screening, and Others), Purchasing Model (One-time License and Subscription Based), End-user (Pharmaceutical & Biotechnology, Research Institutes, Regulatory Authorities, Contract Research Organizations, and Others), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size,Trends, and Forecast 2023 – 2031
Upcoming
| Report ID :HC-5634
| 4.2 Rating
| 83 Reviews
| 199 Pages
| Format :
Report Description
The global drug modeling software market size was USD 7 Billion in 2022 and is likely to reach USD 11.5 Billion by 2031, expanding at a CAGR of 8.5% during 2023–2031. The market growth is attributed to the increasing demand for drug discovery & development activities.
Drug modeling software plays a vital role in the pharmaceutical industry by providing computational tools and algorithms that aid in the development, design, and optimization of new drugs. Drug development refers to the activities performed in the transformation of components obtained during the drug discovery process, into a product used to treat conditions. These products are then authorized and regulated by different regulatory bodies. Drug development, drug discovery, and commercialization is the process of creating a new drug product.
- In May 2023, Fujitsu launched the Biodrug Design Accelerator platform to increase peptide drug discovery research. This platform helps peptide drug discovery scientists in pharmaceutical industries to speed up and increases the efficiency of peptide drug development, especially through the cycles “design, make, test, analyze” (DMTA), ultimately allowing faster and informed design of peptide drug candidates and effective communication among scientists about synthesis and testing.
Artificial Intelligence Impact on Drug Modeling Software Market
Artificial intelligence (AI) technologies are expected to boost the drug discovery modeling market during the forecast period. AI tools help researchers to rapidly examine large-scale data sets, design new molecules, and predict the efficiency of potential drugs. AI delivers value in small-molecule drug discovery in various ways such as access to new biology, improved success rates, and cheaper and quicker discovery processes. ·
- According to a recent analysis report by Boston Consulting Group, biotech companies using an AI-first approach, have above 150 small-molecule drugs in the pipeline by March 2022, and above 15 small-molecule drugs are in clinical trials. This AI-fueled pipeline is increasing at an annual rate of nearly 40%.
AI uses computer software programs that learn, evaluate, and reveal pharmaceutical data to solve new medicine molecules, by integrating the advances in ML in a highly combined and mechanized way. With machine learning, large amounts of data, including drug and molecular data are used to build complex models automatically. These factorsare likely to increase the demand for the drug discovery modeling market.
Drug Modeling Software Market Dynamics
Major Drivers
High demand for innovative therapies is expected to drive the drug modeling software market during the forecast period.The adoption of drug modeling software is closely related to the increasing demand for innovative therapeutics in the pharmaceutical sector. Drug modeling software is crucial for increasing drug potential, accelerating the drug research and development process, and growing the success rate of innovative therapeutics. The increasing prevalence of chronic diseases drives the demand for innovative therapeutics that provide better disease management, outcomes, and good quality of life for patients.
-
According to the World Health Organization (WHO), Chronic diseases kill around 41 million individuals each year, equal to 74% of all deaths worldwide. Around 17 million individuals die from a chronic disease before the age of 70 and 86% of premature deaths occurin developing countries each year.
Existing Restraints
Lack of procedure for multi-drug effect assessment is expected to hinder the drug modeling software market. The effects of multi-drug are known as polypharmacy. The emergence of multiple drug-resistant and extensively drug-resistant bacteria worldwide poses a major threat to human health and defines the need to develop new, effective, and cheap anti-bacterial agents.
Emerging Opportunities
Increasing demand for cloud computing and data analysis technology is expected to create lucrative opportunities for the market players.Several organizations are using this technology to handle vast amounts of data with better automation, mimic human intelligence, generate data-driven insights, and others. Several pharmaceutical and biotechnology companies are taking advantage of this technology to enhance their process of manufacturing, drug research, and development.
-
In June 2022, Certara a global leader in bio-simulation, introduced a new Simcyp Discovery Simulator a new software that is designed for scientists working in small molecule drug discovery and translational research. Simcyp Discovery increases confidence in early-stage development decisions by using physiologically-based pharmacokinetic (PBPK) modeling and simulation, that is derived from the industry-leading Simcyp Simulator.
Scope of Drug Modeling Software Market Report
The market report includes an assessment of the market trends, market segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Drug Modeling Software Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Component (Services and Software), Deployment Mode (Hybrid, Cloud, and On-premise), Enterprise Size (Small & Medium Enterprises and Large Enterprises), Application (Medical Imaging, Protein Modeling, Cheminformatics, Drug Discovery & Development, Graphical Molecular Modeling, High Throughput Virtual Screening, and Others), Purchasing Model (One-time License and Subscription Based), andEnd-user (Pharmaceutical & Biotechnology, Research Institutes, Regulatory Authorities, Contract Research Organizations, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, MarketTrends, and Revenue Forecast |
|
Key Players Covered in the Report |
XtalPi Inc.; VeriSIM Life; The Scripps Research Institute; Simulations Plus; NVIDIA Corporation; Nanome Inc.; InSilicoTrials Technologies; GROUPE DASSAULT; Certara, USA; BC Platforms; and Atomwise Inc |
Drug Modeling Software Market Segment Insights
Component Segment Analysis
Based on component, the drug modeling software market is divided intoservices and software.The software segment is expected to expand at a significant pace during the projection period, owing to the cost-effective drug discovery and designing methods.Software and model-based tool discovery, has become an important method of drug discovery & development in the pharmaceutical industry. This is playing an important role in the expansion of new bioactive drugs in many therapeutic areas. Appropriate usage of software and computer-based modern methods haslessened many barriers to drug discovery and accelerated new drug development.
Deployment Mode Segment Analysis
On the basis of deployment mode, the global market is segregated into hybrid, cloud, and on-premise.The cloud segment is projected to register a considerable CAGR during the forecast period, as it extracts important health information from unstructured medical text such as prescriptions, diagnoses, and reports.Cloud-based models help to streamline the life cycle of artificial intelligence and machine learning in drug discovery.
Enterprise Size Segment Analysis
In terms of enterprise size, the drug modeling software market is segmented into small & medium enterprises and large enterprises.The large enterprises segment is expected to register a robust growth rate during the forecast period. Large enterprises use drug modeling software to reduce the time and cost of drug development, as well as to improve the quality and efficacy of the drugs. Some examples of large enterprises that use drug modeling software such as Pfizer, Merck, GlaxoSmithKline, and Novartis.
Application Segment Analysis
Based on application, the global market is bifurcated into medical imaging, protein modeling, cheminformatics, drug discovery & development, graphical molecular modeling, high through put virtual screening, and others. The drug discovery & development segment is anticipated to hold a key share of the market in the coming years, due to the increasing need for better therapeutic agents for different diseases.The drug discovery process is complex and involves an inter disciplinary effort to design practical and commercially viable drugs. In pharmaceutical, medicinal, and other scientific research, a computer plays an important role in the development of new compounds in search of better therapeutic agents.
Purchasing Model Segment Analysis
On the basis of purchasing model, the drug modeling software market is segmented into one-time license and subscription-based. The one-time license segment is anticipated to account for a major market share in the coming years, as it allows the client to enter the single delivery of a product and is not based on an ongoing subscription. One-time licenses keep things simple for users. It does not need any subscription, or additional payments, and set reminders for cancelation. One-time purchase or license is popular among users who don't want to pledge to ongoing payments or don't have ongoing services.
End-user Segment Analysis
Based on end-user, the global market is segregated into pharmaceutical & biotechnology, research institutes, regulatory authorities, contract research organizations, and others. The pharmaceutical & biotechnology segment is projected to hold a large market share in the coming years. The growth of the market is attributed to, developed algorithms, processed data, performing modeling, and stimulation of drug discovery a development. Engineers and scientists in the biotechnology and pharmaceutical industries use Simulink and MATLAB for integrative data analysis and end-to-end workflows.
Regional Analysis
In terms of region, the global drug modeling software market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, owing to the increasing drug discovery &development activities and high demand for novel therapies. Personalized medicine and intervention of artificial intelligence in drug modeling is increasing in emerging countries such as the US. The regional market growth is attributed to the increasing adoption of in-silico modeling technologies in drug discovery and the rising financial burden of drug discovery.
The market in Asia Pacific is anticipated to expand at a rapid pace in the coming years, due to the high adoption of modeling tools in drug discovery. Emerging countries such as China is expected to dominate the market, owing to the increasing technological advancements.
Segments
The global drug modeling software market has been segmented on the basis of
Component
- Services
- Software
Deployment Mode
- Hybrid
- Cloud
- On-premise
Enterprise Size
- Small & Medium Enterprises
- Large Enterprises
Application
- Medical Imaging
- Protein Modeling
- Cheminformatics
- Drug Discovery & Development
- Graphical Molecular Modeling
- High Throughput Virtual Screening
- Others
Purchasing Model
- One-time License
- Subscription Based
End-user
- Pharmaceutical & Biotechnology Companies
- Research Institutes
- Regulatory Authorities
- Contract Research Organizations
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- XtalPi Inc.
- VeriSIM Life
- The Scripps Research Institute
- Simulations Plus
- NVIDIA Corporation
- Nanome Inc.
- InSilicoTrials Technologies
- GROUPE DASSAULT
- Certara, USA
- BC Platforms
- Atomwise Inc
Competitive Landscape
Key players competing in the global drug modeling software market are XtalPi Inc.; VeriSIM Life; The Scripps Research Institute; Simulations Plus; NVIDIA Corporation; Nanome Inc.; InSilicoTrials Technologies; GROUPE DASSAULT; Certara, USA; BC Platforms; and Atomwise Inc
These key players adopt various strategies including mergers, acquisitions, collaboration, partnerships, product launches, and production expansion to expand their consumer base globally.
- In March 2023, NVIDIA introduced a set of generative AI cloud services for personalizing AI foundation models to increase the manufacturing of new therapeutics and proteins and also research in the fields of biology, chemistry, genomics, and molecular dynamics.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Drug Modeling Software Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Drug Modeling Software Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Drug Modeling Software Market - Supply Chain
4.5. Global Drug Modeling Software Market Forecast
4.5.1. Drug Modeling Software Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Drug Modeling Software Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Drug Modeling Software Market Absolute $ Opportunity
5. Global Drug Modeling Software Market Analysis and Forecast by Applications
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Applications
5.2.2. Y-o-Y Growth Projections by Applications
5.3. Drug Modeling Software Market Size and Volume Forecast by Applications
5.3.1. Medical Imaging
5.3.2. Protein Modeling
5.3.3. Cheminformatics
5.3.4. Drug Discovery & Development
5.3.5. Graphical Molecular Modeling
5.3.6. High Throughput Virtual Screening
5.3.7. Others
5.4. Absolute $ Opportunity Assessment by Applications
5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Drug Modeling Software Market Analysis and Forecast by End Users
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by End Users
6.2.2. Y-o-Y Growth Projections by End Users
6.3. Drug Modeling Software Market Size and Volume Forecast by End Users
6.3.1. Pharmaceutical & Biotechnology Companies
6.3.2. Research Institutes
6.3.3. Regulatory Authorities
6.3.4. Contract Research Organizations
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by End Users
6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Drug Modeling Software Market Analysis and Forecast by Region
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Region
7.2.2. Y-o-Y Growth Projections by Region
7.3. Drug Modeling Software Market Size and Volume Forecast by Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Europe
7.3.4. Asia Pacific
7.3.5. Middle East and Africa (MEA)
7.4. Absolute $ Opportunity Assessment by Region
7.5. Market Attractiveness/Growth Potential Analysis by Region
7.6. Global Drug Modeling Software Demand Share Forecast, 2019-2026
8. North America Drug Modeling Software Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.2. North America Drug Modeling Software Market Size and Volume Forecast by Country
8.2.1. U.S.
8.2.2. Canada
8.3. Absolute $ Opportunity Assessment by Country
8.4. North America Drug Modeling Software Market Size and Volume Forecast by Applications
8.4.1. Medical Imaging
8.4.2. Protein Modeling
8.4.3. Cheminformatics
8.4.4. Drug Discovery & Development
8.4.5. Graphical Molecular Modeling
8.4.6. High Throughput Virtual Screening
8.4.7. Others
8.5. Basis Point Share (BPS) Analysis by Applications
8.6. Y-o-Y Growth Projections by Applications
8.7. North America Drug Modeling Software Market Size and Volume Forecast by End Users
8.7.1. Pharmaceutical & Biotechnology Companies
8.7.2. Research Institutes
8.7.3. Regulatory Authorities
8.7.4. Contract Research Organizations
8.7.5. Others
8.8. Basis Point Share (BPS) Analysis by End Users
8.9. Y-o-Y Growth Projections by End Users
8.10. Market Attractiveness/Growth Potential Analysis
8.10.1. By Country
8.10.2. By Product Type
8.10.3. By Application
8.11. North America Drug Modeling Software Demand Share Forecast, 2019-2026
9. Latin America Drug Modeling Software Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Latin America Average Pricing Analysis
9.2. Latin America Drug Modeling Software Market Size and Volume Forecast by Country
9.2.1. Brazil
9.2.2. Mexico
9.2.3. Rest of Latin America
9.3. Absolute $ Opportunity Assessment by Country
9.4. Latin America Drug Modeling Software Market Size and Volume Forecast by Applications
9.4.1. Medical Imaging
9.4.2. Protein Modeling
9.4.3. Cheminformatics
9.4.4. Drug Discovery & Development
9.4.5. Graphical Molecular Modeling
9.4.6. High Throughput Virtual Screening
9.4.7. Others
9.5. Basis Point Share (BPS) Analysis by Applications
9.6. Y-o-Y Growth Projections by Applications
9.7. Latin America Drug Modeling Software Market Size and Volume Forecast by End Users
9.7.1. Pharmaceutical & Biotechnology Companies
9.7.2. Research Institutes
9.7.3. Regulatory Authorities
9.7.4. Contract Research Organizations
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by End Users
9.9. Y-o-Y Growth Projections by End Users
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.11. Latin America Drug Modeling Software Demand Share Forecast, 2019-2026
10. Europe Drug Modeling Software Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Europe Average Pricing Analysis
10.2. Europe Drug Modeling Software Market Size and Volume Forecast by Country
10.2.1. Germany
10.2.2. France
10.2.3. Italy
10.2.4. U.K.
10.2.5. Spain
10.2.6. Russia
10.2.7. Rest of Europe
10.3. Absolute $ Opportunity Assessment by Country
10.4. Europe Drug Modeling Software Market Size and Volume Forecast by Applications
10.4.1. Medical Imaging
10.4.2. Protein Modeling
10.4.3. Cheminformatics
10.4.4. Drug Discovery & Development
10.4.5. Graphical Molecular Modeling
10.4.6. High Throughput Virtual Screening
10.4.7. Others
10.5. Basis Point Share (BPS) Analysis by Applications
10.6. Y-o-Y Growth Projections by Applications
10.7. Europe Drug Modeling Software Market Size and Volume Forecast by End Users
10.7.1. Pharmaceutical & Biotechnology Companies
10.7.2. Research Institutes
10.7.3. Regulatory Authorities
10.7.4. Contract Research Organizations
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by End Users
10.9. Y-o-Y Growth Projections by End Users
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.11. Europe Drug Modeling Software Demand Share Forecast, 2019-2026
11. Asia Pacific Drug Modeling Software Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Asia Pacific Average Pricing Analysis
11.2. Asia Pacific Drug Modeling Software Market Size and Volume Forecast by Country
11.2.1. China
11.2.2. Japan
11.2.3. South Korea
11.2.4. India
11.2.5. Australia
11.2.6. Rest of Asia Pacific (APAC)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Asia Pacific Drug Modeling Software Market Size and Volume Forecast by Applications
11.4.1. Medical Imaging
11.4.2. Protein Modeling
11.4.3. Cheminformatics
11.4.4. Drug Discovery & Development
11.4.5. Graphical Molecular Modeling
11.4.6. High Throughput Virtual Screening
11.4.7. Others
11.5. Basis Point Share (BPS) Analysis by Applications
11.6. Y-o-Y Growth Projections by Applications
11.7. Asia Pacific Drug Modeling Software Market Size and Volume Forecast by End Users
11.7.1. Pharmaceutical & Biotechnology Companies
11.7.2. Research Institutes
11.7.3. Regulatory Authorities
11.7.4. Contract Research Organizations
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by End Users
11.9. Y-o-Y Growth Projections by End Users
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.11. Asia Pacific Drug Modeling Software Demand Share Forecast, 2019-2026
12. Middle East & Africa Drug Modeling Software Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Middle East & Africa Average Pricing Analysis
12.2. Middle East & Africa Drug Modeling Software Market Size and Volume Forecast by Country
12.2.1. Saudi Arabia
12.2.2. South Africa
12.2.3. UAE
12.2.4. Rest of Middle East & Africa (MEA)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Middle East & Africa Drug Modeling Software Market Size and Volume Forecast by Applications
12.4.1. Medical Imaging
12.4.2. Protein Modeling
12.4.3. Cheminformatics
12.4.4. Drug Discovery & Development
12.4.5. Graphical Molecular Modeling
12.4.6. High Throughput Virtual Screening
12.4.7. Others
12.5. Basis Point Share (BPS) Analysis by Applications
12.6. Y-o-Y Growth Projections by Applications
12.7. Middle East & Africa Drug Modeling Software Market Size and Volume Forecast by End Users
12.7.1. Pharmaceutical & Biotechnology Companies
12.7.2. Research Institutes
12.7.3. Regulatory Authorities
12.7.4. Contract Research Organizations
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by End Users
12.9. Y-o-Y Growth Projections by End Users
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.11. Middle East & Africa Drug Modeling Software Demand Share Forecast, 2019-2026
13. Competition Landscape
13.1. Global Drug Modeling Software Market: Market Share Analysis
13.2. Drug Modeling Software Distributors and Customers
13.3. Drug Modeling Software Market: Competitive Dashboard
13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
13.4.1. XtalPi Inc.
13.4.2. VeriSIM Life
13.4.3. The Scripps Research Institute
13.4.4. Simulations Plus
13.4.5. NVIDIA Corporation
13.4.6. Nanome Inc.
13.4.7. InSilicoTrials Technologies
13.4.8. GROUPE DASSAULT
13.4.9. Certara, USA
13.4.10. BC Platforms
13.4.11. Atomwise Inc
Methodology
Related Reports
Some other reports from this category!
Our Clients
